Understanding how certain cancers develop and how to treat them better
Project 1 - Epigenetic Control of Normal and Malignant Neuroendocrine Differentiation
This study is looking at how certain tough-to-treat cancers, like small cell lung cancer and neuroendocrine prostate cancer, develop and change, with the hope of finding new ways to treat them by understanding the genes and factors involved.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11016329 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind neuroendocrine differentiation in various difficult-to-treat cancers, such as small cell lung cancer and neuroendocrine prostate cancer. By examining the genetic and regulatory factors that influence these cancers, the project aims to uncover new treatment strategies that could be effective across different cancer types. The researchers have developed a novel human cellular model to study the normal development of neuroendocrine cells, which may provide insights into how these cells can become cancerous. The ultimate goal is to identify common pathways that can be targeted for therapy, regardless of the cancer's tissue origin.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with neuroendocrine tumors or those with treatment-resistant prostate cancer.
Not a fit: Patients with non-neuroendocrine cancers or those without a diagnosis of prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with neuroendocrine cancers.
How similar studies have performed: Other research has shown promise in targeting common pathways in neuroendocrine cancers, suggesting that this approach could yield significant advancements.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Shivdasani, Ramesh a — Dana-Farber Cancer Inst
- Study coordinator: Shivdasani, Ramesh a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.